申请人:Cadila Pharmaceuticals Ltd.
公开号:US10882819B2
公开(公告)日:2021-01-05
The present invention relates to novel intermediate(s), which are useful for the preparation of Rivastigmine compound of formula (I) and its pharmaceutically acceptable salts. The present invention further relates to the processes for the preparation of such novel intermediate(s) and preparation of Rivastigmine using such novel intermediate(s).
本发明涉及新型中间体,可用于制备式(I)的利伐斯的明化合物及其药学上可接受的盐类。本发明还涉及制备此类新型中间体和使用此类新型中间体制备利伐斯的明的工艺。